Author

L. A. Gibson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. Padhye· 1 shared B. L. Rodriguez· 1 shared C. A. Class· 1 shared D. H. Peng· 1 shared D. L. Gibbons· 1 shared J. J. Fradette· 1 shared J. K. Ochieng· 1 shared J. Wang· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Padhye

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivJun 7, 2020

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers

D. H. Peng, B. L. Rodriguez, L. Diao…·D. L. Gibbons

This study shows that Th17 cells contribute to resistance to MEK inhibitor and anti-PD-L1 therapy in KRAS/p53 mutant lung cancers and suggests a triple combinatorial therapy to overcome resistance.

DOI 10.1038/s41467-021-22875-w

mousebulk RNA-seq

𝕏 PostBluesky